No results for ‘’
Jagsonpal Pharmaceuticals Ltd
₹212.28
(0.82%)
Tue, 23 Jun 2026, 03:43 am
Health Technology
Pharmaceuticals: Generic
24.5KJagsonpal Pharmaceuticals Return on Equity (ROE) History
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 30.30 | 15.79 | 13.33 | 3.29 | 5.51 | 5.72 | 4.49 | 14.44 | 12.64 | 63.33 | 26.41 | 8.41 | 0 | 9.55 | 5.81 | 12.22 | 43.57 | 28.42 | 33.04 | 26.26 |
| Price to book ratio | 1.13 | 0.61 | 0.54 | 0.25 | 0.58 | 0.44 | 0.34 | 0.27 | 0.27 | 0.78 | 0.87 | 0.91 | 0.72 | 0.66 | 0.41 | 1.71 | 6.19 | 4.78 | 3.95 | 5.98 |
| Price to sales ratio | 0.51 | 0.34 | 0.27 | 0.15 | 0.37 | 0.25 | 0.19 | 0.16 | 0.19 | 0.54 | 0.60 | 0.69 | 0.56 | 0.41 | 0.29 | 1.11 | 3.78 | 3.21 | 3.56 | 5.41 |
| Price to cash flow ratio | 50.05 | 18.70 | 2.97 | 0.99 | 59.58 | 6.35 | 12.30 | 3.86 | 12.56 | 0 | 22.93 | 0 | 0 | 2.29 | 3.38 | 6.93 | 100.50 | 15.21 | 17.46 | 23.06 |
| Enterprise value | 118Cr | 90.11Cr | 74.96Cr | 41.22Cr | 65.6Cr | 62.29Cr | 58.52Cr | 49.55Cr | 50.18Cr | 99.25Cr | 109Cr | 87.68Cr | 64.26Cr | 34.15Cr | 12.31Cr | 153Cr | 775Cr | 651Cr | 603Cr | 1335Cr |
| Enterprise value to EBITDA ratio | 8.70 | 8.29 | 5.95 | 2.73 | 4.17 | 4.29 | 3.52 | 4.92 | 4.70 | 11.37 | 9.21 | 14.35 | 0 | 3.66 | 1.43 | 8.01 | 29.63 | 18.40 | 25.46 | 25.82 |
| Debt to equity ratio | 0.60 | 0.68 | 0.54 | 0.35 | 0.23 | 0.31 | 0.35 | 0.34 | 0.36 | 0.41 | 0.39 | 0.07 | 0.08 | 0.04 | 0.06 | 0.06 | 0 | 0.04 | 0.05 | 0.04 |
| Return on equity % | 0 | 3.93 | 4.17 | 7.95 | 11.02 | 7.96 | 7.79 | 1.86 | 2.15 | 1.21 | 3.36 | 11.39 | -11.11 | 7.13 | 7.30 | 14.64 | 14.81 | 18.44 | 12.97 | 25.91 |
Jagsonpal Pharmaceuticals Ltd Return on Equity
The Jagsonpal Pharmaceuticals Ltd Return on Equity is a key financial metric used by investors to evaluate Jagsonpal Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Jagsonpal Pharmaceuticals Ltd Return on Equity helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Jagsonpal Pharmaceuticals Ltd (NSE: JAGSNPHARM, BSE: 507789) is currently trading at ₹212.28, with a market capitalization of ₹1425.7Cr. As a leading company in the Health technology sector and Pharmaceuticals: generic industry, monitoring the Jagsonpal Pharmaceuticals Ltd Return on Equity is essential for fundamental analysis.
Jagsonpal Pharmaceuticals Ltd Return on Equity Current Value
The current Jagsonpal Pharmaceuticals Ltd Return on Equity stands at 25.91.
The latest Jagsonpal Pharmaceuticals Ltd Return on Equity has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Jagsonpal Pharmaceuticals Ltd Return on Equity Historical Trend
The Jagsonpal Pharmaceuticals Ltd Return on Equity has shown the following historical trend:
- 2024: 25.91
- 2023: 12.97
- 2022: 18.44
- 2021: 14.81
- 2020: 14.64
The recent rise in Jagsonpal Pharmaceuticals Ltd Return on Equity suggests strengthening valuation trends and improving market sentiment.
What Jagsonpal Pharmaceuticals Ltd Return on Equity Indicates for Investors
The Jagsonpal Pharmaceuticals Ltd Return on Equity plays a crucial role in understanding the company's financial health and valuation.
ROE indicates how efficiently the company generates returns for shareholders.
Jagsonpal Pharmaceuticals Ltd Return on Equity Analysis Summary
The Jagsonpal Pharmaceuticals Ltd Return on Equity remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Jagsonpal Pharmaceuticals Ltd Return on Equity should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Jagsonpal Pharmaceuticals Ltd Return on Equity helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.